Mumbai, India

Amol Anant Kadam

This inventor holds 1 USPTO granted patent. Top assignee: Glenmark Pharmaceuticals Limited. Active years: 2018.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Amol Anant Kadam. Retrieved from https://idiyas.com/inventor/amol-anant-kadam

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile


Average Co-Inventor Count = 6.0

ph-index = 1


Company Filing History:


Years Active: 2018

Loading Chart...
1 patent (USPTO):Explore Patents

Title: Amol Anant Kadam: Innovator in Pharmaceutical Chemistry

Introduction

Amol Anant Kadam is a notable inventor based in Mumbai, India. He has made significant contributions to the field of pharmaceutical chemistry, particularly through his innovative processes.

Latest Patents

Amol holds a patent for the "Process for preparation of azelaic acid." This patent outlines a method for synthesizing azelaic acid, which is widely used in various pharmaceutical applications.

Career Highlights

Amol is currently employed at Glenmark Pharmaceuticals Limited, a prominent player in the pharmaceutical industry. His work focuses on developing processes that enhance the efficiency and effectiveness of drug formulations.

Collaborations

Amol has collaborated with several talented professionals, including Shekhar Bhaskar Bhirud and Kumar Hari Bhushan. These collaborations have contributed to the advancement of innovative solutions in the pharmaceutical sector.

Conclusion

Amol Anant Kadam's contributions to pharmaceutical chemistry, particularly through his patent on azelaic acid, highlight his role as an innovator in the industry. His work at Glenmark Pharmaceuticals Limited and collaborations with other professionals further emphasize his commitment to advancing pharmaceutical science.

Profile summary based on public USPTO records.
Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…